EICHOR
● Recruiting
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
Condition: Nasopharyngeal Carcinoma · Sponsor: XIANG YANQUN
About this study
This study aims to evaluate the efficacy and safety of the TPC regimen (nab-paclitaxel, cisplatin, and capecitabine) combined with apatinib and camrelizumab versus the GP regimen (gemcitabine and cisplatin) combined with camrelizumab for the treatment of high-risk regionally advanced nasopharyngeal carcinoma with a high risk of distant metastasis. The evaluation will be conducted through a prospective, controlled, open-label, multicenter phase 3 clinical trial in areas with high incidence of nasopharyngeal carcinoma.
This description comes directly from the study's public registry record.
Talk to the study team
Yanqun Xiang · 18666096623 · xiangyq@syscc.org.cn
Guoying Liu · 18127919832 · liugy0109@163.com
Always discuss trial participation with your own doctor first.
Locations (2)
| SunYat-senU | Guangzhou, Guangdong, China | Recruiting |
| Sun Yat sen Memorial Hospital | Guangzhou, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.